TSX News -
Kerr Mines Announces Closing of $5 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN […]
VISLINK TECHNOLOGIES, INC. Second Quarter 2020 Earnings Update
HACKETTSTOWN, NJ, Aug. 10, 2020 (GLOBE NEWSWIRE) — Vislink Technologies, Inc. (NASDAQ: VISL) (the “Company”) plans to release the results […]
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
Preclinical data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020Interim Analysis Results for Phase […]
UCLOUDLINK GROUP INC. to Report Second Quarter 2020 Financial Results on August 17, 2020
HONG KONG, Aug. 10, 2020 (GLOBE NEWSWIRE) — UCLOUDLINK GROUP INC. (“uCloudlink” or the “Company”) (NASDAQ: UCL), the world’s first […]
Entera Bio Announces Management Changes
BOSTON and JERUSALEM, Aug. 10, 2020 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of […]
Fluent, Inc. to Present at the 40th Annual Canaccord Genuity Growth Conference
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, today announced that […]
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, […]
iFresh Announces Entry into Definitive Agreement to Acquire Jiuxiang Blue Sky Technology (Beijing) Co., Ltd.
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) — iFresh, Inc. (“iFresh” or the “Company”) (Nasdaq: IFMK), a leading Asian American […]
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at 56 Week Analysis of Phase 1/2 Open-Label Extension StudyInitiated […]
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
Early Interim Data from Registrational Phase 2 TRIDENT-1 Study of Lead Drug Candidate Repotrectinib Anticipated in Third QuarterFour Clinical Studies […]
